Rimantadine for treatment of hepatitis C infection in liver transplant recipients

Liver Transplantation and Surgery

Volumn 5, Issue 1, 1999, Pages 25-28

  Sherman, K E ^a   Sickler, J ^a   Aranda Michel, J ^a   Weber, F L ^a   Martin, S ^a   Whiting, J ^a   Hanto, D ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; RIMANTADINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER TRANSPLANTATION; MALE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0032956430     PISSN: 10743022     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.500050103     Document Type: Article

References (14)

1. 1 Wright TL, Donegan E, Hsu HH, Ferrell L, Lake JR, Kim M, et al. Recurrent and acquired hepatitis C infection in liver transplant recipients. Gastroenterology 1992 ; 103: 317–322. MEDLINE
2. 2 Gane EJ, Portaman BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long‐term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996 ; 334: 815–820. MEDLINE
3. 3 Sheiner PA, Schwartz ME, Mor E, Schluger LK, Theise N, Kishikawa K, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995 ; 21: 30–34. MEDLINE
4. 4 Lim HL, Lau GKK, Davis GL, Dolson DJ, Lau JYN. Cholestatic hepatitis leading to hepatic failure in a patient with organ‐transmitted hepatitis C infection. Gastroenterology 1994 ; 106: 248–251. MEDLINE
5. 5 Wright TL, Combs C, Kim M, Ferrell L, Bacchetti P, Ascher N, et al. Interferon‐α therapy for hepatitis C virus infection after liver transplantation. Hepatology 1994 ; 20: 773–779. MEDLINE
6. 6 Feray C, Samuel D, Gigou M, Paradis V, David MF, Lemonnier C, et al. An open trial of interferon alfa recombinant for hepatitis C after transplantation: Antiviral effects and risk of rejection. Hepatology 1995 ; 22: 1084–1089. MEDLINE
7. 7 Cattral MS, Krajden M, Wanless IR, Rezig M, Cameron R, Greig PD, et al. A pilot study of ribavirin therapy for recurrent hepatitis C virus infection after liver transplantation. Transplantation 1996 ; 61: 1483–1488. MEDLINE
8. 8 Smith JP. Treatment of chronic hepatitis C with amantadine. Dig Dis Sci 1997 ; 42: 1681–1687. MEDLINE
9. 9 Sherman KE, Mendenhall C, Thee DL, O'Brien J, Rouster SD. Hepatitis C serotypes in nonalcoholic and alcoholic patients. Dig Dis Sci 1997 ; 42: 2285–2291. MEDLINE
10. 10 Hay AJ. The action of adamantadines against influenza A viruses; Inhibition of the M2 ion channel protein. Semin Virol 1992 ; 3: 21–30.
11. 11 Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989 ; 321: 1501–1506. MEDLINE
12. 12 Di Bisceglie AM, Martin P, Kassianides C, Lisker‐Melman M, Goodman Z, Banks SM, Hoofnagle JH. A randomized, double‐blind, placebo‐controlled trial of recombinant human alpha‐interferon therapy for chronic non‐A, non‐B (type C) hepatitis. J Hepatol 1990 ; 11 (suppl 1): S36–S42. MEDLINE
13. 13 Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnenberg A, Weiland O. Randomised, double‐blind, placebo‐controlled trial of interferon alpha‐2b with and without ribavirin for chronic hepatitis C. Lancet 1998 ; 351: 83–87. MEDLINE
14. 14 Gane EJ, Lo SK, Riordan SM, Portman BC, Lau JY, Naoumov NV, Williams R. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998 ; 27: 1403–1407. MEDLINE